Integrating diagnostics and therapeutics: revolutionizing drug discovery and patient care.
Over the next five years it is widely anticipated that the molecular diagnostics industry will continue to grow at double-digit pace to meet increasing demand for personalized medicine. A wide variety of drugs in late preclinical and early clinical development is now being targeted to disease-specific gene and protein defects that will require co-approval of diagnostic and therapeutic products by regulatory agencies. For clinical laboratories and pathologists, this integration of diagnostics and therapeutics represents a major new opportunity to emerge as leaders of the new medicine, guiding the selection, dosage, route of administration and multi-drug combinations, and producing increased efficacy and reduced toxicity of pharmaceutical products.
Ross
Jeffrey S
JS
Millennium Pharmaceuticals, 38 Sidney Street, Cambridge, MA 02138, USA. ross@mpi.com
Ginsburg
Geoffrey S
GS
D000818:Animals; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008967:Molecular Biology; D010770:Phosphotransferases / Q000037:antagonists & inhibitors / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects* / Q000235:genetics*
D004791:Enzyme Inhibitors; D010770:Phosphotransferases